These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 39314240)

  • 1. β-hydroxybutyrate recapitulates the beneficial effects of ketogenic metabolic therapy in polycystic kidney disease.
    Torres JA; Holznecht N; Asplund DA; Kroes BC; Amarlkhagva T; Haeffner MM; Sharpe EH; Koestner S; Strubl S; Schimmel MF; Kruger S; Agrawal S; Aceves BA; Thangaraju M; Weimbs T
    iScience; 2024 Sep; 27(9):110773. PubMed ID: 39314240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease.
    Torres JA; Holznecht N; Asplund DA; Amarlkhagva T; Kroes BC; Rebello J; Agrawal S; Weimbs T
    Am J Physiol Renal Physiol; 2024 Mar; 326(3):F352-F368. PubMed ID: 38095025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease.
    Torres JA; Kruger SL; Broderick C; Amarlkhagva T; Agrawal S; Dodam JR; Mrug M; Lyons LA; Weimbs T
    Cell Metab; 2019 Dec; 30(6):1007-1023.e5. PubMed ID: 31631001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease.
    Oehm S; Steinke K; Schmidt J; Arjune S; Todorova P; Heinrich Lindemann C; Wöstmann F; Meyer F; Siedek F; Weimbs T; Müller RU; Grundmann F
    Nephrol Dial Transplant; 2023 Jun; 38(7):1623-1635. PubMed ID: 36423335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketogenic Interventions in Autosomal Dominant Polycystic Kidney Disease: A Comprehensive Review of Current Evidence.
    Pezzuoli C; Biagini G; Magistroni R
    Nutrients; 2024 Aug; 16(16):. PubMed ID: 39203812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
    Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
    Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease.
    Hopp K; Kleczko EK; Gitomer BY; Chonchol M; Klawitter J; Christians U; Klawitter J
    Am J Physiol Renal Physiol; 2022 Mar; 322(3):F258-F267. PubMed ID: 35037466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic derangement in polycystic kidney disease mouse models is ameliorated by mitochondrial-targeted antioxidants.
    Daneshgar N; Baguley AW; Liang PI; Wu F; Chu Y; Kinter MT; Benavides GA; Johnson MS; Darley-Usmar V; Zhang J; Chan KS; Dai DF
    Commun Biol; 2021 Oct; 4(1):1200. PubMed ID: 34671066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential Add-On Benefits of Dietary Intervention in the Treatment of Autosomal Dominant Polycystic Kidney Disease.
    Rosati E; Condello G; Tacente C; Mariani I; Tommolini V; Calvaruso L; Fulignati P; Grandaliano G; Pesce F
    Nutrients; 2024 Aug; 16(16):. PubMed ID: 39203719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.
    Jamadar A; Suma SM; Mathew S; Fields TA; Wallace DP; Calvet JP; Rao R
    Cell Death Dis; 2021 Oct; 12(10):947. PubMed ID: 34650051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased mitochondrial fragmentation in polycystic kidney disease acts as a modifier of disease progression.
    Cassina L; Chiaravalli M; Boletta A
    FASEB J; 2020 May; 34(5):6493-6507. PubMed ID: 32239723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parallel analysis of mRNA and microRNA microarray profiles to explore functional regulatory patterns in polycystic kidney disease: using PKD/Mhm rat model.
    Dweep H; Sticht C; Kharkar A; Pandey P; Gretz N
    PLoS One; 2013; 8(1):e53780. PubMed ID: 23326503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease.
    Pickel L; Iliuta IA; Scholey J; Pei Y; Sung HK
    Adv Nutr; 2022 Mar; 13(2):652-666. PubMed ID: 34755831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ablation of Long Noncoding RNA Hoxb3os Exacerbates Cystogenesis in Mouse Polycystic Kidney Disease.
    Weisser I; Eckberg K; D'Amico S; Buttram D; Aboudehen K
    J Am Soc Nephrol; 2024 Jan; 35(1):41-55. PubMed ID: 37953472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of a modified low protein and low fat diet on histologic changes and metabolism in kidneys in an experimental model of polycystic kidney disease].
    Banković-Calić N; Ogbori MR; Nicman E
    Srp Arh Celok Lek; 2002; 130(7-8):251-7. PubMed ID: 12585002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of hydration in rats and mice with polycystic kidney disease.
    Hopp K; Wang X; Ye H; Irazabal MV; Harris PC; Torres VE
    Am J Physiol Renal Physiol; 2015 Feb; 308(3):F261-6. PubMed ID: 25503729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
    Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
    Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scattered Deletion of PKD1 in Kidneys Causes a Cystic Snowball Effect and Recapitulates Polycystic Kidney Disease.
    Leonhard WN; Zandbergen M; Veraar K; van den Berg S; van der Weerd L; Breuning M; de Heer E; Peters DJ
    J Am Soc Nephrol; 2015 Jun; 26(6):1322-33. PubMed ID: 25361818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1
    Arroyo J; Escobar-Zarate D; Wells HH; Constans MM; Thao K; Smith JM; Sieben CJ; Martell MR; Kline TL; Irazabal MV; Torres VE; Hopp K; Harris PC
    Kidney Int; 2021 Jun; 99(6):1392-1407. PubMed ID: 33705824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of transcription factor profiles in polycystic kidney disease (PKD): identification and validation of STAT3 and RUNX1 in the injury/repair response and PKD progression.
    Formica C; Malas T; Balog J; Verburg L; 't Hoen PAC; Peters DJM
    J Mol Med (Berl); 2019 Dec; 97(12):1643-1656. PubMed ID: 31773180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.